Bidirectional Association Between Premenstrual Disorders and Psychiatric Disorders - Report - MDSpire

Bidirectional Association Between Premenstrual Disorders and Psychiatric Disorders

  • By

  • Jing Zhou

  • Zeinab Muse

  • Emma Bränn

  • Yihui Yang

  • Elgeta Hysaj

  • Miriam Martini

  • Nora E. Verberne

  • Marion Opatowski

  • Astrid Kamperman

  • Helena Kopp Kallner

  • Elizabeth Bertone-Johnson

  • Donghao Lu

  • May 8, 2026

  • 0 min

Share

Clinical Report: Reciprocal Relationship Between Premenstrual Disorders and Mental Health Conditions

Overview

This study investigates the bidirectional association between premenstrual disorders (PMD) and psychiatric conditions, revealing that women with PMD are significantly more likely to experience major depression and generalized anxiety disorders. The findings underscore the importance of recognizing and addressing the mental health implications of PMD.

Background

Premenstrual disorders, including PMS and PMDD, affect a substantial proportion of women, leading to significant emotional and physical symptoms that can impair quality of life. Understanding the relationship between PMD and psychiatric disorders is crucial for improving diagnosis and treatment strategies, as these conditions often co-occur and influence each other. The bidirectional nature of this relationship highlights the need for integrated care approaches in managing women's health.

Data Highlights

No numerical data available in the provided source material.

Key Findings

  • Women with PMD are 4 times more likely to have major depression and 7 times more likely to have generalized anxiety disorders.
  • There is a bidirectional association between PMD and psychiatric disorders, particularly depression and anxiety.
  • Higher co-occurrence rates of PMD with bipolar disorder, PTSD, and ADHD have been reported.
  • Genetic factors may contribute to the shared risk between PMD and psychiatric disorders, with heritability estimates ranging from 35% to 56%.
  • Only two prospective studies have documented increased risks of depression and bipolar disorder following a PMD diagnosis.

Clinical Implications

Healthcare providers should be vigilant in screening for psychiatric disorders in women diagnosed with PMD, given the high rates of comorbidity. Integrated treatment approaches that address both PMD and associated mental health conditions may improve patient outcomes and quality of life.

Conclusion

The findings of this study emphasize the complex interplay between premenstrual disorders and mental health conditions, necessitating a comprehensive approach to diagnosis and treatment in affected women.

Related Resources & Content

  1. BMC Psychiatry (Springer) — Trait- versus state- grey matter volume alterations in premenstrual dysphoric disorder
  2. BMC Psychiatry (Springer) — Effects of sleep quality on the default mode network and on anxiety-depression symptoms in premenstrual syndrome
  3. BMC Psychiatry (Springer) — Exploring the role of obesity in predicting mental health disorders: analyzing the effects of diagnosis sequence order
  4. BMC Psychiatry (Springer) — Sex-specific associations of episode type in bipolar I disorder with neuro-metabolic lateralization of the cortico-striatal-cerebellar (CSC) circuit
  5. Premenstrual Disorders: Guidelines From the American College of Obstetricians and Gynecologists | AAFP
  6. A systematic review and meta-analysis on the comorbidity of premenstrual dysphoric disorder or premenstrual syndrome with mood disorders: prevalence, clinical and neurobiological correlates
  7. What are the benefits and risks of treating premenstrual syndrome and premenstrual dysphoric disorder with selective serotonin reuptake inhibitors? | Cochrane
  8. Premenstrual Disorders: Guidelines From the American College of Obstetricians and Gynecologists | AAFP
  9. A systematic review and meta-analysis on the comorbidity of premenstrual dysphoric disorder or premenstrual syndrome with mood disorders: prevalence, clinical and neurobiological correlates‡
  10. What are the benefits and risks of treating premenstrual syndrome and premenstrual dysphoric disorder with selective serotonin reuptake inhibitors? | Cochrane

Original Source(s)

Related Content